These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 8968017)

  • 1. Occult prostate cancer in men with low serum testosterone levels.
    Morgentaler A; Bruning CO; DeWolf WC
    JAMA; 1996 Dec; 276(23):1904-6. PubMed ID: 8968017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
    Morgentaler A; Rhoden EL
    Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormonal predictors of prostate cancer.
    Sofikerim M; Eskicorapci S; Oruç O; Ozen H
    Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./ml. Prostate specific antigen.
    Lodding P; Aus G; Bergdahl S; Frösing R; Lilja H; Pihl CG; Hugosson J
    J Urol; 1998 Mar; 159(3):899-903. PubMed ID: 9474178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.
    Catalona WJ; Smith DS; Ornstein DK
    JAMA; 1997 May; 277(18):1452-5. PubMed ID: 9145717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of percent free prostate specific antigen and prostate specific antigen density as methods to enhance prostate specific antigen specificity in early prostate cancer detection in men with normal rectal examination and prostate specific antigen between 4.1 and 10 ng./ml.
    Morote J; Raventós CX; Lorente JA; Lopez-Pacios MA; Encabo G; de Torres I; Andreu J
    J Urol; 1997 Aug; 158(2):502-4. PubMed ID: 9224333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.
    Catalona WJ; Smith DS; Wolfert RL; Wang TJ; Rittenhouse HG; Ratliff TL; Nadler RB
    JAMA; 1995 Oct; 274(15):1214-20. PubMed ID: 7563511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher sex hormone-binding globulin and lower bioavailable testosterone are related to prostate cancer detection on prostate biopsy.
    García-Cruz E; Carrión Puig A; García-Larrosa A; Sallent A; Castañeda-Argáiz R; Piqueras M; Ribal MJ; Leibar-Tamayo A; Romero-Otero J; Alcaraz A
    Scand J Urol; 2013 Aug; 47(4):282-9. PubMed ID: 23181478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of prostate cancer at different levels of serum prostate-specific antigen (PSA) and different free: total PSA ratios in a consecutive series of men referred for prostate biopsies.
    Rydén L; Egevad L; Ekman P; Hellström M
    Scand J Urol Nephrol; 2007; 41(4):302-7. PubMed ID: 17763221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of serum prostate-specific antigen levels with the results of the prostate needle biopsy.
    Janbaziroudsari H; Mirzaei A; Maleki N
    Bull Cancer; 2016 Sep; 103(9):730-4. PubMed ID: 27345449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1,051 men.
    Djavan B; Zlotta A; Remzi M; Ghawidel K; Basharkhah A; Schulman CC; Marberger M
    J Urol; 2000 Apr; 163(4):1144-8; discussion 1148-9. PubMed ID: 10737484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of digital rectal examination and needle biopsy on serum total and percentage of free prostate specific antigen levels.
    Ornstein DK; Rao GS; Smith DS; Ratliff TL; Basler JW; Catalona WJ
    J Urol; 1997 Jan; 157(1):195-8. PubMed ID: 8976249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment.
    García-Cruz E; Piqueras M; Huguet J; Peri L; Izquierdo L; Musquera M; Franco A; Alvarez-Vijande R; Ribal MJ; Alcaraz A
    BJU Int; 2012 Dec; 110(11 Pt B):E541-6. PubMed ID: 22584031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A; Dworschack RT; Partin AW
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.
    Thompson IM; Pauler DK; Goodman PJ; Tangen CM; Lucia MS; Parnes HL; Minasian LM; Ford LG; Lippman SM; Crawford ED; Crowley JJ; Coltman CA
    N Engl J Med; 2004 May; 350(22):2239-46. PubMed ID: 15163773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk.
    Morote J; Planas J; Ramirez C; Gómez E; Raventós CX; Placer J; Catalán R; de Torres IM
    BJU Int; 2010 Feb; 105(4):481-4. PubMed ID: 19681902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness.
    Morote J; Ramirez C; Gómez E; Planas J; Raventós CX; de Torres IM; Catalán R
    BJU Int; 2009 Aug; 104(4):486-9. PubMed ID: 19220251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of Prostate Biopsy in Men with Hypogonadism Prior or During Testosterone Replacement Therapy.
    Shoskes DA; Barazani Y; Fareed K; Sabanegh E
    Int Braz J Urol; 2015; 41(6):1167-71. PubMed ID: 26742976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of prostate volume, age, total prostate specific antigen level and acute inflammation on the percentage of free serum prostate specific antigen levels in men without clinically detectable prostate cancer.
    Ornstein DK; Smith DS; Humphrey PA; Catalona WJ
    J Urol; 1998 Apr; 159(4):1234-7. PubMed ID: 9507843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.
    Thompson IM; Ankerst DP; Chi C; Lucia MS; Goodman PJ; Crowley JJ; Parnes HL; Coltman CA
    JAMA; 2005 Jul; 294(1):66-70. PubMed ID: 15998892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.